NCT04274465Completed
Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia
Application of Plasma Circulating Human Papillomavirus (HPV) DNA Testing to Management of Cervical Intraepithelial Neoplasia
Source: ClinicalTrials.gov · Last updated 14 Nov 2024
Brief summary (registry, in English)
The purpose of this study is to see if circulating HPV DNA (cHPVDNA) can be used as a noninvasive biomarker for cervical intraepithelial neoplasia (CIN) 2-3 in hopes of reducing procedures and costs for patients, as well as personalize their treatment plan.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 145 (actual)
- First submitted
- 14 Feb 2020
- Start date
- 26 Feb 2020
- Primary completion date
- 26 Jun 2024
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Diseases
- Cervical cancer
- NCT number
- NCT04274465
What you commit to
- Study type: Observational
- Participants enrolled: 145
- From 26 Feb 2020 to the primary completion date, 26 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Women who are pregnant or nursing
Who the study is looking for
- No history of previously treated cervical cancer
- Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee
Age in the registry: 18 years to 99 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tuvara Jenene King Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.